Publications by authors named "Robert Croop"

16Publications

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.

Lancet 2021 Jan 15;397(10268):51-60. Epub 2020 Dec 15.

NIHR-Wellcome Trust King's Clinical Research Facility, King's College Hospital/SLaM Biomedical Research Centre, King's College London, UK; University of California, Los Angeles, Los Angeles, CA, USA.

View Article and Find Full Text PDF
January 2021

Pain Freedom at 2-8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant: A Response.

Headache 2020 Nov;60(10):2611-2612

Biostatistics, Biohaven Pharmaceuticals Holding Company Ltd, New Haven, CT, USA.

View Article and Find Full Text PDF
November 2020

Testing rimegepant for migraine-time to revise the trial design? - Authors' reply.

Lancet 2020 06;395(10241):1901-1902

Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.

View Article and Find Full Text PDF
June 2020

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.

Neurology 2020 05 13;94(20):e2121-e2125. Epub 2020 Jan 13.

From the New England Institute of Neurology and Headache (K.M.), Stamford, CT; California Medical Clinic for Headache (D.K.), Santa Monica; Biohaven Pharmaceuticals, Inc (R.C., M.L., C.M.C., V.C.), New Haven, CT; and Albert Einstein College of Medicine (R.B.L.), Bronx, NY.

View Article and Find Full Text PDF
May 2020

Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.

N Engl J Med 2019 07;381(2):142-149

From the Departments of Neurology and Epidemiology and Population Health, Albert Einstein College of Medicine, and Montefiore Medical Center - both in Bronx, NY (R.B.L.); Biohaven Pharmaceuticals, New Haven, CT (R.C., E.G.S., D.A.S., B.A.M., M.F., G.M.D., C.M.C., V.C.); NIHR-Wellcome Trust King's Clinical Research Facility, King's College Hospital-South London and Maudsley Biomedical Research Centre, King's College London, London (P.J.G.); and the University of California, San Francisco, San Francisco (P.J.G.).

View Article and Find Full Text PDF
July 2019

Development of oral extended release formulations of 6-hydroxybuspirone.

Biopharm Drug Dispos 2012 Dec 12;33(9):522-35. Epub 2012 Nov 12.

Drug Product Science and Technology, Research and Development, Bristol-Myers Squibb, Moreton, Merseyside CH46 1QW, UK.

View Article and Find Full Text PDF
December 2012

Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects.

J Clin Pharmacol 2010 Oct 11;50(10):1211-6. Epub 2010 Feb 11.

Bristol-Myers Squibb Company, PO Box 4000, Princeton, NJ 08543, USA.

View Article and Find Full Text PDF
October 2010

Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?

Am J Physiol Gastrointest Liver Physiol 2009 Jun 2;296(6):G1299-306. Epub 2009 Apr 2.

Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.

View Article and Find Full Text PDF
June 2009

Pharmacokinetics of 6-hydroxybuspirone and its enantiomers administered individually or following buspirone administration in humans.

Biopharm Drug Dispos 2007 Oct;28(7):393-402

Clinical Discovery, Bristol-Myers Squibb Company, Princeton, NJ 08543, USA.

View Article and Find Full Text PDF
October 2007